Curagen Corp

Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 8-K 4 pages This Second Supplemental Indenture, Dated as of December 31, 2009 (This “Second Supplemental Indenture”), Is by and Among Curagen Corporation (The “Curagen”), Celldex Therapeutics, Inc. (“Celldex”) and the Bank of New York Mellon (Formerly, the Bank of New York), as Trustee Under the Indenture Referred to Below (The “Trustee”)
12/34/56
EX-4.1
from 8-K 8 pages This Supplemental Indenture, Dated as of September 30, 2009 (This “Supplemental Indenture”), Is by and Among Curagen Corporation (The “Company”), Celldex Therapeutics, Inc. (“Parent”) and the Bank of New York Mellon (Formerly, the Bank of New York), as Trustee Under the Indenture Referred to Below (The “Trustee”)
12/34/56
EX-4.1
from DEFA14A 6 pages Amendment to the Stockholder Rights Agreement
12/34/56
EX-4.1
from 8-K 6 pages Amendment to the Stockholder Rights Agreement
12/34/56
EX-4.1
from 10-Q 23 pages Curagen Corporation Amended and Restated By-Laws
12/34/56
EX-4.5
from 10-K 105 pages Curagen Corporation as Issuer the Bank of New York, as Trustee Up to $120,000,000 Aggregate Principal Amount of 4.0% Convertible Subordinated Notes Due 2011 Indenture Dated as of February 17, 2004
12/34/56
EX-4.4
from 10-K ~50 pages Stockholder Rights Agreement
12/34/56
EX-4.2
from S-3 ~50 pages Exhibit 4.2 - Form of Subordinated Indenture
12/34/56
EX-4.1
from S-3 ~50 pages Exhibit 4.1 - Form of Senior Indenture
12/34/56
EX-4.2
from S-3 ~20 pages Registration Rights Agreement Dated 02/02/2000
12/34/56
EX-4.1
from S-3 >50 pages Indenture Dated 02/02/2000
12/34/56
EX-4.2
from S-1/A 1 page Form of Common Stock Certificate
12/34/56